A study by ManafiFarid et al., that reviewed the literature on patients with mCRPC who underwent radioligand therapy with [177Lu]Lu-PSMA found that the presence of lymph node metastasis was associated with a higher rate of biochemical response and longer progression-free survival [20]. This evidence concerns the gene FOLH1 and metastatic malignant neoplasm in the lymph nodes.